Search

Diseases can affect men and women differently. We must acknowledge and accept that – and then optimize drug development accordingly

Acknowledging the shortcomings in IBD-related clinical trials and a potential holistic approach to overcoming them

The benefits of closed processing are well-documented, but what about the sustainability angle?

How the drive to try something new led to the development of lentiviral vectors for gene therapy.

It’s already used for processing powders in many industries, but here’s why pastillation should come to pharma next.

Cardinal Health’s Fran Gregory looks at innovative payment models for cell and gene therapies.

Sitting Down With Christian Baber of the Pistoia Alliance

How quantum mechanics and machine learning can be combined to develop new drugs

CRISPR tech in antibody manufacturing, sterilization of single-use systems, and more! Check out our eBook.

Cardinal Health’s Fran Gregory talks about the high costs of cell and gene therapies, and what this means for payers.